chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Two huge lymph nodes in lungs (both); Both her knees down to her feet are swollen; Hot to the touch; Six spots that are really really red; Can not walk; One huge lymph protruding from the side of her neck; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PULMONARY MASS (Two huge lymph nodes in lungs (both)), JOINT SWELLING (Both her knees down to her feet are swollen), FEELING HOT (Hot to the touch), ERYTHEMA (Six spots that are really really red) and GAIT INABILITY (Can not walk) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In August 2021, the patient experienced JOINT SWELLING (Both her knees down to her feet are swollen), FEELING HOT (Hot to the touch), ERYTHEMA (Six spots that are really really red), GAIT INABILITY (Can not walk) and LYMPHADENOPATHY (One huge lymph protruding from the side of her neck). On an unknown date, the patient experienced PULMONARY MASS (Two huge lymph nodes in lungs (both)). At the time of the report, PULMONARY MASS (Two huge lymph nodes in lungs (both)), JOINT SWELLING (Both her knees down to her feet are swollen), FEELING HOT (Hot to the touch), ERYTHEMA (Six spots that are really really red), GAIT INABILITY (Can not walk) and LYMPHADENOPATHY (One huge lymph protruding from the side of her neck) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: 186 (High) 186 over 108, sent to the hospital because of her blood pressure and heart rate. On an unknown date, Heart rate: 117 (High) Sent to the hospital because of her blood pressure and heart rate.         Concomitant medication use information was  provided by reporter that includes Blood pressure medicine. Treatment medication use information was not provided by reporter.  Patient was healthy up until the shot. Patient reported that side effects were not improving even though was seen by physicians.   Most recent FOLLOW-UP information incorporated above includes: On 29-Aug-2021: Follow up received on 29- Aug-2021, added reporter contact details, event outcome updated from unknown to not recovered , added information in I narrative.
Information has been received from a healthcare worker (also reported as medical assistant) who reported that a female consumer reported her daughter on an unspecified date (prior to 26-JAN-2011) was vaccinated with PNEUMOVAX 23 (lot # not reported). On an unknown date the patient developed a fever, redness, warmth and induration of 3-4 inches at the injection site and rash at the injection site. It was unspecified if the patient sought medical attention. At the time of reporting, the patient's outcome was unknown. Follow up information has been received from the healthcare worker who reported that the patient experienced pain, swelling, redness, warm to touch, fever after receiving the vaccine. At the time of reporting, the patient's outcome was unknown. The healthcare worker mentioned the patient's brother also had a similar reaction to PNEUMOVAX 23, which was reported in WAES # 1103USA01404. Additional information has been requested.
Wife called stated that they took the train into the city after leaving clinic, had lunch. Started "shaking" denies any SOB, difficulty breathing or swallowing at present. Assured wife instructed  on was of Benadryl and to activate 911 if any increase signs and symptoms or difficulty breathing.
Sever ache in lower back to the left side, which radiated to groin area accompanied with chills, constipation and slightly bloody stool.
Patient reported bruising at and below the injection site. Today (12/22), she reported slight soreness above the injection site.
Immediately after given vaccine (IM), pt's (L) arm began to bruise and swell very quickly. I asked pt if he had any other sx and he reported no other sx. I had pt stay seated and hold an ice pack over the area for 20 minutes. I continued to talk to him to assess his status during those 20 min. After 20 min. swelling decreased significantly and pt went home.
Injection site itching; Injection site redness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Injection site itching) and VACCINATION SITE ERYTHEMA (Injection site redness) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A20A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (Injection site itching) and VACCINATION SITE ERYTHEMA (Injection site redness). At the time of the report, VACCINATION SITE PRURITUS (Injection site itching) and VACCINATION SITE ERYTHEMA (Injection site redness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  Treatment information was not provided.
Information has been received from a physician and a practice manager via company representative referring to a patient of unknown age and gender. On 10-DEC-2014 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23-10PK- 0.5mlSD-PFS LLokwTip) (lot # K019386, expiration date 09-JUN-2016). This specified lot number vaccine was exposed to temperature excursion once.  The total cumulative excursion time 48 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
p/vax pt devel T100; relieved w/tylenol;denies rash; itching; sore throat or any other symptoms
Pregnancy; pain at the injection site; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) and VACCINATION SITE PAIN (pain at the injection site) in a 30-year-old female patient (gravida 3) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     The patient's past medical history included Miscarriage (3 ). Concurrent medical conditions included Blood pressure high. Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] from 01-Aug-2017 to an unknown date for Pregnancy, CALCIUM and ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.    On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 01-Aug-2020 and the estimated date of delivery was 08-May-2021. On 24-Feb-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) and VACCINATION SITE PAIN (pain at the injection site). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-ninth week of the pregnancy.  On 24-Feb-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) had resolved. At the time of the report, VACCINATION SITE PAIN (pain at the injection site) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood glucose: inconclusive (Inconclusive) Inconclusive. On an unknown date, Ultrasound testes: normal (normal) healthy outcome.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Treatment information for the event was provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 25-Feb-2021: Lab data, pregnancy details, concomitant medication were updated.
8/11/99 vomiting up to 6x day; T102; given pedialyte only;8/12/99 hx of no stools, rectal exam revealed guaiac + stool; BE done w/partial reduction of intussusception;surgery; appendix nl; still in hosp;
Rash down both arms; On/off dizzy spells; Nausea; Migraine; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Jul2021 at 18:15 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety. The patient received unspecified medication within two weeks of vaccination. The patient previously took oxycodone (MANUFACTURER UNKNOWN) and hydrocodone (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Jul2021 at 21:30, the patient experienced rash down both arms, on and off dizzy spells, nausea and migraine. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events rash down both arms, on and off dizzy spells, nausea and migraine were not resolved at the time of this report.   The lot number for BNT162b2 was not provided and will be requested during follow-up.
Headaches, nausea, menstrual changes, drowsiness, fatigue x 2-3 weeks
Patient had one of her typical seizures on 3/14/21. She did not seek care. She managed at home and called 2 days later to notify my office that the seizure had taken place . She was feeling well.
Fever; chills; night sweats; hot flashes; increased heart rate; chest pain; nausea; swelling at the injection site; pain at the injection site; rash at the injection site; rash elsewhere on my body; fatigue; headache; decrease appetite. Had symptoms at least 7-9 days. I took advil. I tried cool compresses and cool baths. Employee health quarantined me and I got COVID tested.
The vial expiration date was 13-Oct-2021 and date of vial placed in refrigerator before administration was on 29-Oct-2021; Dose was given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose was given after expiration date) and PRODUCT STORAGE ERROR (The vial expiration date was 13-Oct-2021 and date of vial placed in refrigerator before administration was on 29-Oct-2021) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose was given after expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial expiration date was 13-Oct-2021 and date of vial placed in refrigerator before administration was on 29-Oct-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose was given after expiration date) and PRODUCT STORAGE ERROR (The vial expiration date was 13-Oct-2021 and date of vial placed in refrigerator before administration was on 29-Oct-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. It was reported that there was a confusion between the expiration date printed in the carton and the expiration date when the quick response code was scanned. The vaccine had not undergone any temperature excursion and patient had not experienced any adverse event. No treatment medications were reported.   This case was linked to MOD-2022-491837 (Patient Link).
8 Hours after administration of vaccine patient began to shiver uncontrollably. He proceeded to the ER & stayed for a few hours until shivering was over.
side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (side effects) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (side effects). At the time of the report, VACCINATION COMPLICATION (side effects) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Relevant concomitant product usage were not reported by the reporter. No treatment details were added. Action taken with mRNA-1273 in response to the event was not applicable.
injection site redness, with warmth to touch; injection site redness, with warmth to touch; injection site redness, with warmth to touch; hives spread down their arm; Initial information received on 18-Nov-2019 regarding an unsolicited valid non-serious case from a consumer/non-health care professional (Office Staff).  This case is linked to cases 2019SA322706 and 2019SA327308.  This case involves a female (age not reported) patient of unknown age who had injection site redness, with warmth to touch (vaccination site inflammation) and hives spread down their arm (urticaria), while she received vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].  The patient's past medical history, medical treatment(s), vaccination(s) and family history and concomitant therapies were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (lot number: UT6719KA and expiry date: 30-Jun-2020) via unknown route in unknown administration site.  On an unknown date, the patient had injection site redness, with warmth to touch (vaccination site inflammation, vaccination site erythema, vaccination site warmth) and hives spread down their arm (urticaria), (Unknown latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE..  No lab data was not reported.  Final diagnosis was vaccination site urticaria and vaccination site inflammation.  It was not reported if the patient received a corrective treatment.  The patient outcome was reported as Unknown for all events.
TIREDNESS, SLIGHT HEADACHE, MUSCLE ACHES, LACK OF APPETITE; ONGOING AS OF JUNE 10, 10:45 AM.
Arm hurt down to the middle of the bone and didn't stop until the last couple of days.
COVID infection and provider prescribed paxlovid/Missed taking the bivalent vaccine/been a while since she was boosted; COVID infection and provider prescribed paxlovid/Missed taking the bivalent vaccine/been a while since she was boosted; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 70-year-old female patient received BNT162b2 (BNT162B2), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "COVID infection and provider prescribed paxlovid/Missed taking the bivalent vaccine/been a while since she was boosted". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: finished a course of paxlovid. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: She is 70 years of age and had not been boosted in a while. She notes that she couldn't find the time to "get sick" as she often does after she receives vaccines. Caller says from what she has read, it "looks like you cannot get a vaccine right away if you have finished a course of paxlovid, but if it was monoclonal treatment you can have it right away." Will file for AE reported regarding "vaccines" identified after call. Appreciate taking the Paxlovid it's an amazing drug and I hope Pfizer gets it approved more than what it is already approved.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
It was a few days after my 2nd does I had head pressure and a pulsing sensation on both ears but stronger on my right ear. By March 2nd I started to get a ringing sound in my ears and it has never stopped. I got seen by an audiologist and was diagnosed with pulsatile tinnitus and was given referral to local location to see a head and neck specialist.
pt recvd vax & was sweating; inc t 103; very fatigue & weak; atrial flutter; admitted to hosp;
Got flu shot on 12/2/08 and on 12/4/2008 had severe pain and edema in ankle and foot and with in a week total joint involvement. MD visit follow week for the issue and MD opinion was an immune response to the flu shot. Serum sickness ruled out because of duration of symptoms. Best guess was flu shot triggered an immune repsones that opened the door for Rheumtoid Arthritis.
Serious pain on the right arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Serious pain on the right arm) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026C2A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes, Prostate cancer, Bladder cancer and Hypertension.    On 09-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Serious pain on the right arm). At the time of the report, PAIN IN EXTREMITY (Serious pain on the right arm) had not resolved.            No concomitant medication details was reported. No treatment medication details was reported.
Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Error: Shoulder Joint Injury (prolonged pain, tingling, etc.)
RMA gave Kinrix instead of Tdap. Patient is fine but I had advise RMA to give Tdap and Ipol separate. She gave Kinrix because she thought of one shot over two shots.
Rash at injection site, sore and swollen lymph node near injection site (bicep)
On 06/03/21, developed swelling following COVID-19 Pfizer Vaccine and developed VTE L IJ and subclavian vein
painful/burning; burning; broke out in hives; This case was reported by a physician via sales rep and described the occurrence of injection site pain in a 66-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of injection site pain (For tolerance of 1st dose of Shingrix, refer linked case US2019AMR226348).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced injection site pain, injection site hives and hives. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the injection site pain, injection site hives and hives were unknown.   The reporter considered the injection site pain, injection site hives and hives to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. After Shingrix vaccination the patient experienced very burning painful,broke out in hives at the injection and around her neck.
Headache; Nausea; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Apr2021 at 11:30 (at the age of 59-years-old), as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not have any allergies to medications, food, or other products. Concomitant medications included escitalopram (MANUFACTURER UNKNOWN), valacyclovir (MANUFACTURER UNKNOWN), zolmitriptan (MANUFACTURER UNKNOWN) and fish oil (MANUFACTURER UNKNOWN), all taken for unknown indications from unknown dates. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 07:00, the patient experienced headache with nausea and fatigue. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events headache with nausea and fatigue was resolved on an unknown date in Apr2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
His arm and shoulder bothered him, he cannot stand, he had a slight fever 100.2 on Sunday two days after, and now he can't walk.
pt devel hypotension, diarrhea, fever, nausea/vomiting;
I work nights and when I got home at 0600 I started having severe chills and felt very cold; I work nights and when I got home at 0600 I started having severe chills and felt very cold; Sore arm for 12 hours; Fell asleep at 0810 and woke up feeling hot and dehydrated. And nauseas; Fell asleep at 0810 and woke up feeling hot and dehydrated. And nauseas; Fell asleep at 0810 and woke up feeling hot and dehydrated. And nauseas; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 10May2021 at 16:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 10May2021 at 16:15, the patient experienced sore arm for 12 hours. On 11May2021 at 06:00, the patient experienced severe chills and felt very cold. On an unknown date in May2021, the patient fell asleep at 08:10 and woke up feeling hot, dehydrated and nauseous. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event sore arm for 12 hours was resolved on 11May2021 at 04:15, after the duration of 12 hours; while that of the events woke up feeling hot, dehydrated and nauseous, severe chills and felt very cold was resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.